Analytical Triple Agonist

Retatrutide LY3437943

A breakthrough in unimolecular polypharmacology. Advanced 39-amino acid triple-agonist peptide (C₂₂₁H₃₄₂N₄₆O₆₈) targeting the GIP, GLP-1, and Glucagon pathways.

Molecular Engineering Data

Molecular FormulaC₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight4731.33 g/mol

CAS Registry2381089-83-2

Physical StateAcetate Salt Solid

Binding Affinity (GIPR)EC50: 0.06nM

Assay (HPLC)>99.0% Purity

The “Triple-G” Agonist Cascade

Retatrutide represents the evolution of polypharmacology, advancing beyond dual-agonists to engage three distinct G-protein coupled receptors (GPCRs) simultaneously. This unimolecular design triggers a unique metabolic signal cascade, investigated for its profound influence on glucose homeostasis, appetite suppression, and hepatic fat oxidation. By integrating the Glucagon receptor (GCGR) alongside the established GIP and GLP-1 pathways, researchers can observe shifts in energy expenditure and lipid mobilisation not possible with previous-generation peptides.

GIPR
Primary Modulator

Exhibiting the strongest affinity, GIPR agonism is studied for its role in insulin secretion and white adipose tissue metabolic efficiency.

GCGR
The Glucagon Factor

GCGR activation targets hepatic fat oxidation and metabolic thermogenesis, potentially driving significant shifts in basal energy expenditure.

Structural Blueprint

The 4731.33 Da structure is a highly stable linear sequence engineered for multi-receptor affinity. Research focus remains on the specific amino acid residues that facilitate simultaneous binding to the GLP-1R (0.77nM) and GCGR (5.79nM) sites.

Retatrutide Structure

Comparative Benchmarks

Triple Agonism: GIP + GLP-1 + GCGR (Retatrutide)
Dual Agonism: GIP + GLP-1 (Tirzepatide)
Single Agonism: GLP-1 only (Semaglutide)
Lipidomics: Direct Glucagon-mediated fat oxidation.
Energy: Non-shivering thermogenesis induction.

Key Research Benchmarks

In metabolic models, Retatrutide is extensively investigated for its impact on Hepatic Steatosis reversal and Glomerular Permeability. Researchers often map the activation of Adenylate Cyclase and the subsequent secondary messenger spikes (cAMP) to determine the volumetric efficiency of the triple-signalling pathway.

Thermogenesis
Investigating the activation of brown adipose tissue (BAT) through combined GLP-1 and Glucagon agonism.

Lipid Mobilisation
Analysis of shifts in triglyceride fractions and hepatic lipid profile clearance under GCGR engagement.

Laboratory Protocol & Handling

Storage & Stability
Supplied lyophilised for maximum sequence integrity during logistics.

Dry Storage: -20°C for >12 months; 2-8°C for <6 months.
Liquid Stability: Must be refrigerated (2-8°C) once reconstituted.
Solubility: Water (5mg/ml), PBS, or DMSO.

Reconstitution SOP
Strict adherence to laboratory SOPs is required to maintain the 39-amino acid chain.

Solvent: Sterile Bacteriostatic Water or PBS.
Technique: Slow sidewall induction; do not agitate the puck.
Unit Sizes: 20mg, 30mg, 40mg, and 60mg configurations.

Strict Laboratory Compliance Notice

WARNING: This compound is a chemical reagent supplied exclusively for in-vitro and in-vivo laboratory research. It is NOT a drug, medication, or food supplement. Strictly prohibited for human or veterinary administration. Lawful handling is the sole responsibility of the professional user. HRS Distribution assumes no liability for applications outside of laboratory scientific research.